The United States is considering new tariffs targeting pharmaceutical products and copper imports as part of a broader effort to strengthen domestic manufacturing and reduce dependence on overseas supply chains. The proposal reflects a growing emphasis on economic security, particularly for industries regarded as strategically important to national interests. Pharmaceutical manufacturing has become a major policy focus following disruptions experienced during the COVID-19 pandemic. Shortages of medicines, active pharmaceutical ingredients (APIs) and medical supplies exposed vulnerabilities in global supply chains, prompting governments worldwide to reassess production capacity and diversify sourcing strategies. Copper has also emerged as a critical industrial commodity because of its central role in electricity transmission, renewable energy systems, electric vehicles and artificial intelligence infrastructure. Rising demand from data centers, battery manufacturing and grid modernization has increased concerns about securing reliable long-term supplies. Supporters of tariffs argue that higher import costs could encourage companies to expand domestic production, create manufacturing jobs and strengthen supply chain resilience. They contend that reducing dependence on foreign suppliers would improve national security while supporting long-term industrial competitiveness. Critics warn that tariffs could increase production costs for manufacturers that rely on imported raw materials or pharmaceutical ingredients. Those higher costs may eventually be passed on to businesses and consumers, potentially contributing to inflationary pressures while disrupting established global supply chains. International trading partners are closely monitoring the proposal, as new tariffs could influence trade negotiations and prompt reciprocal measures. Global manufacturers may also adjust investment decisions depending on how future trade policies evolve. Economists emphasize that industrial policy involves balancing domestic production incentives against the benefits of international trade. While greater manufacturing capacity can improve resilience, policymakers must also consider impacts on prices, competitiveness and consumer access to essential products. The outcome of the proposed tariff review could significantly influence investment decisions across healthcare, mining, manufacturing and infrastructure industries. Businesses are expected to closely monitor future policy announcements while evaluating potential changes to sourcing strategies and production planning.